Cargando…

Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms

Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management. Yet, a preventive or curative panacea for sustained AF does not exist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geng, Meng, Lin, Andrew, Nguyen, Thao P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680856/ https://www.ncbi.nlm.nih.gov/pubmed/33240090 http://dx.doi.org/10.3389/fphar.2020.581837

Ejemplares similares

Emerging Antiarrhythmic Drugs for Atrial Fibrillation
por: Saljic, Arnela, et al.
Publicado: (2022)

Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium Channels
por: Ratte, Antonius, et al.
Publicado: (2019)

Revisiting the Role of Antiarrhythmic Drugs in Prevention of Atrial Fibrillation Recurrence: A Single Center Retrospective Review
por: Mascarenhas, Daniel AN, et al.
Publicado: (2018)

Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging
por: Dan, Gheorghe-Andrei, et al.
Publicado: (2018)

Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation
por: Reiffel, James A.
Publicado: (2018)

Prior antiarrhythmic drug use and the outcome of atrial fibrillation ablation
por: Winkle, Roger A., et al.
Publicado: (2012)

Computational Modeling for Antiarrhythmic Drugs for Atrial Fibrillation According to Genotype
por: Hwang, Inseok, et al.
Publicado: (2021)

Corrigendum: Computational modeling for antiarrhythmic drugs for atrial fibrillation according to genotype
por: Hwang, Inseok, et al.
Publicado: (2022)

Impact of Antiarrhythmic Drugs on the Outcome of Short QT Syndrome
por: El-Battrawy, Ibrahim, et al.
Publicado: (2019)

Revisiting an Underrecognized Strategy for Rhythm Management: Hybrid Therapy for Patients who Convert from Atrial Fibrillation to Flutter on Antiarrhythmic Drugs
por: Riad, Fady S., et al.
Publicado: (2019)

Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation
por: Verrier, Richard L., et al.
Publicado: (2020)

Non-traditional antiarrhythmic drugs as upstream and downstream dam for atrial fibrillation burden
por: Dan, Gheorghe-Andrei
Publicado: (2020)

Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease
por: Pantlin, Peter G., et al.
Publicado: (2020)

Sex difference in atrial fibrillation recurrence after catheter ablation and antiarrhythmic drugs
por: Park, Yoon Jung, et al.
Publicado: (2023)

Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets
por: Karagueuzian, Hrayr S., et al.
Publicado: (2017)

Comparison of Circumferential Pulmonary Vein Isolation and Antiarrhythmic Drug Therapy in Patients with Atrial Fibrillation
por: Xu, Yanmin, et al.
Publicado: (2012)

Evaluation of Index of Cardio-Electrophysiological Balance in Patients With Atrial Fibrillation on Antiarrhythmic-Drug Therapy
por: Afsin, Abdulmecit, et al.
Publicado: (2021)

US Antiarrhythmic Drug Treatment for Patients With Atrial Fibrillation: An Insurance Claims–Based Report
por: Tardos, Jonathan G., et al.
Publicado: (2021)

Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation
por: Heijman, Jordi, et al.
Publicado: (2013)

Electrical Restitution and Its Modifications by Antiarrhythmic Drugs in Undiseased Human Ventricular Muscle
por: Árpádffy-Lovas, Tamás, et al.
Publicado: (2020)

Editorial: Perspectives of Antiarrhythmic Drug Therapy: Disappointing Past, Current Efforts, and Faint Hopes
por: Nánási, Péter P., et al.
Publicado: (2020)

Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study
por: Al-Jazairi, Meelad I H, et al.
Publicado: (2021)

Resource use and clinical outcomes in patients with atrial fibrillation with ablation versus antiarrhythmic drug treatment
por: Jarman, Julian W. E., et al.
Publicado: (2018)

Correction to: Evaluation of Index of Cardio-Electrophysiological Balance in Patients With Atrial Fibrillation on Antiarrhythmic-Drug Therapy
por: Afsin, Abdulmecit, et al.
Publicado: (2021)

Meta‐analysis of cryoballoon ablation versus antiarrhythmic drugs as initial therapy for symptomatic atrial fibrillation
por: Mao, Yin‐jun, et al.
Publicado: (2021)

Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation
por: Kuniss, Malte, et al.
Publicado: (2021)

Heart failure risk in patients with atrial fibrillation treated with catheter ablation vs antiarrhythmic drugs
por: Gruber, Megan, et al.
Publicado: (2023)

Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation
por: Wang, Amy
Publicado: (2012)

Time‐dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses
por: Carstensen, Helena, et al.
Publicado: (2018)

Knots to untie: anticoagulant and antiarrhythmic therapy after ablation for atrial fibrillation
por: Stazi, Filippo
Publicado: (2020)

Late Sodium Current Inhibitors as Potential Antiarrhythmic Agents
por: Horváth, Balázs, et al.
Publicado: (2020)

ARumenamides: A novel class of potential antiarrhythmic compounds
por: Abdelsayed, Mena, et al.
Publicado: (2022)

RAAFT-2: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design
por: Packer, Douglas L., et al.
Publicado: (2018)

Antiarrhythmic drug therapy after catheter ablation for atrial fibrillation—Insights from the German Ablation Registry
por: Schleberger, Ruben, et al.
Publicado: (2021)

Ablation and antiarrhythmic drug effects on PITX2(+/−) deficient atrial fibrillation: A computational modeling study
por: Jin, Ze, et al.
Publicado: (2022)

Atrial Tachycardias Arising from Ablation of Atrial Fibrillation: A Proarrhythmic Bump or an Antiarrhythmic Turn?
por: Shah, Ashok J., et al.
Publicado: (2010)

Effects of antiarrhythmics on atrial high rate episodes and progression to clinical atrial fibrillation (ANTI-AHRE)
por: Simovic, S, et al.
Publicado: (2023)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Antiarrhythmic and Electrophysiologic Effects of Flecainide on Acutely Induced Atrial Fibrillation in Healthy Horses
por: Haugaard, M.M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dvo0qm550p91sjfhdbu53mlf34